PFS and correlative biomarker analysis from the phase 3 coBRIM study

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma.

Year of Production:
Running Time:
Color/Sound:

2015
01:50
Color/Sound

Comments are closed.